Search

everythinglearnresearchcommunity

for

Search:↓

Creatine may affect hair loss by reducing PGE2 levels, which could influence hair growth. The discussion highlights the need for more research on this potential mechanism.

A user's hair regrowth journey using biotin and minoxidil after initial treatments with Nizoral shampoo and Ketoconazole serum didn't work. The comments suggest the hair loss might not be male pattern baldness (MPB), but possibly Alopecia Areata, an autoimmune disorder, and recommend getting a second opinion and considering other treatments like corticosteroids.

A user discussed using KeraXL serum for hair loss, which contains Biochanin-A from Red clover extract and Acetyl Tetrapeptide-3. They sought feedback on its safety and effectiveness.

The user shared progress after 7 months of hair loss treatment using topical minoxidil with finasteride, oral minoxidil, microneedling, LLLT laser cap, and scalp massage. They reported thicker, denser hair with no significant side effects.

The conversation is about hair loss treatments, specifically the anticipation for the release of a new treatment, GT20029, by 2028. Users are discussing their experiences with current treatments like finasteride and dutasteride, and the potential of future treatments, including FAK inhibitors and verteporfin trials.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

A user is seeing good results with RU58841 for hair loss, noting reduced shedding and thicker hair. They plan to use pumpkin seed oil as a solvent to avoid water content, which they believe reduces the effectiveness of anti-androgens.

Scalp tension potentially affecting hair loss, and potential treatments for male pattern baldness such as Minoxidil, Finasteride and RU58841. Evidence from a study was discussed which suggests that the cause of MPB lies within the follicle itself and is not dependent on its surrounding environment.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

ET-02, a PAI-1 inhibitor, is not proven to be more effective than Minoxidil for hair loss. Other treatments like finasteride, dutasteride, PP405, and AMP-303 are also discussed, focusing on cellular senescence and oxidative stress.

RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.

The conversation discusses topical androgen receptor blockers for hair loss, mentioning Clascoterone, Pyrilutamide, GT20029, and RU58841. Ketoconazole's effectiveness and application methods are also debated.

OP is considering using KX-826 for hair loss due to side effects from other treatments like Minoxidil and finasteride. Users discuss the risks and safety of KX-826, with some suggesting caution due to its status as a research chemical.

A 30-year-old shared their 7-month hair regrowth progress using topical minoxidil twice daily, 1 mg finasteride daily, and weekly microneedling. Users discussed the effectiveness of these treatments and suggested adding retinol for better results.

Pumpkin seed oil is discussed as a potential treatment for hair loss, but the study cited is criticized for using a product with multiple ingredients, making it unclear if pumpkin seed oil is effective. The conversation concludes with skepticism about the study's validity and mentions that pumpkin seeds might help with DHT blocking.

A 21-year-old used 1.25mg finasteride and minoxidil twice daily for hair regrowth, reducing finasteride to 5 times a week since September. He also started using Nizoral for dandruff, noticed an increased appetite, and experienced a temporary change in sex drive.

The user is experiencing worsening hair loss despite undergoing monthly injectable finasteride, clay masks, laser therapy, and microneedling. They are concerned about severe shedding in areas not typically affected by male pattern baldness and are considering seeking a second opinion.

A 27-year-old male shared his 7-month hair regrowth progress using finasteride, keto shampoo, rosemary oil, and both oral and topical minoxidil. He experienced initial shedding but is pleased with the results and plans to continue the treatments.

Pyrilutamide (KX826) sourcing and pricing, with users discussing the legitimacy and cost of grey market versus official sources. The conversation highlights the high cost of official products and the effectiveness of grey market versions.

Maneup GHK-Cu peptide was used for hair loss, resulting in some hair growth in the receded hairline, but the new hairs were dry and split easily. Users discussed their experiences with this treatment.

KX-826 failed Phase III trials due to high placebo effects, patient compliance issues, COVID-19 side effects, and detection method deviations. KX-826 is now marketed as a cosmetic and approved for combination with Minoxidil.

A user was frustrated with delays in getting finasteride for hair loss, was prescribed minoxidil, and found a vitamin B7 deficiency. They are questioning if the deficiency could cause receded temples and considering finding a new dermatologist.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841, and highlights hair multiplication research from Koehler Lab at Harvard. Users express optimism about future advancements.

Hair regrowth treatment involving 3aHSD enzyme shows 6% improvement in 18 weeks. Sulforaphane, L-Menthol, and Dexpanthenol are potential ingredients for new hair loss solution.

Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.

The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.